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Abstract
Background: Preparing an antibiotic stewardship program requires detailed information on overall antibiotic use,
prescription indication and ecology. However, longitudinal data of this kind are scarce. Computerization of the
patient chart has offered the potential to collect complete data of high resolution. To gain insight in our global
antibiotic use, we aimed to explore antibiotic prescription in our intensive care unit (ICU) from various angles over a
prolonged time period.
Methods: We studied all adult patients admitted to Ghent University Hospital ICU from 1 January 2013 until 31
December 2016. Antibiotic prescription data were prospectively merged with diagnostic (suspected focus, severity
and probability of infection at the time of prescription, or prophylaxis) and microbiology data by ICU physicians
during daily workflow through dedicated software. Definite focus of infection and probability of infection (classified
as high/moderate/low) were reassessed by dedicated ICU physicians at patient discharge.
Results: During the study period, 8763 patients were admitted and overall antibiotic consumption amounted to
1232 days of therapy (DOT)/1000 patient days. Antibacterial DOT (84% of total DOT) were linked with infection in
80%; the predominant foci were the respiratory tract (49%) and the abdomen (19%). A microbial cause was
identified in 56% (3169/5686). Moderate/low probability infections accounted for 42% of antibacterial DOT
prescribed for respiratory tract infections; for abdominal infections, this figure was 15%. The median treatment
duration of moderate/low probability respiratory infections was 4 days (IQR 3–7). Antifungal DOT (16% of total DOT)
were linked with infection in 47% of total antifungal DOT. Antifungal prophylaxis was primarily administered in the
surgical ICU (76%), with a median duration of 4 DOT (IQR 2–9).
Conclusions: By prospectively combining antibiotic, microbiology and clinical data we were able to construct a
longitudinal, multifaceted dataset on antibiotic use and infection diagnosis. A complete overview of this kind may
allow the identification of antibiotic prescription patterns that require future antibiotic stewardship attention.
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Background
Antibiotics are among the most prescribed drugs in the
intensive care unit (ICU) [1, 2]. The concept of “anti-
biotic stewardship” refers to policies and interventions
to optimize antibiotic therapy and restrict their unneces-
sary use [3–9]. The latter comprises avoiding antibiotic
prescription for non-infectious disease, limiting the use
of broad-spectrum drugs when a narrower antimicrobial
spectrum suffices and shortening duration of therapy
when prolonged antibiotic courses do not provide bene-
fit [10–12].
Surveillance of antibiotic prescription is a first and es-
sential step to measure antibiotic expenditure, to docu-
ment physicians’ incentives to prescribe antibiotics and to
identify areas of potential overuse or misuse which could
then be a target for antimicrobial stewardship interven-
tions [5, 13–15]. In general, surveillance metrics are de-
rived from antibiotic prescription data (pharmacy-based),
microbiology results (laboratory-based) or diagnostic
codes (administration-based) or a combination thereof.
However, surveillance is not the primary purpose of these
sources of information and using them often results in
poor matching of antibiotic prescription data with the cor-
responding clinical and microbiological information. As
such, their ability to represent the complex nature of the
antibiotic treatment decision-making process and thus
their practical usefulness is limited [16–18]. Prospective
surveillance is more precise and informative but, since it
is demanding in time and resources, is usually only ap-
plied for relatively short periods of time or for a limited
scope of prescription, e.g. for certain classes of reserved
antibiotics [19]. However, the computerization of the pa-
tient ICU chart has nowadays offered the potential to rec-
ord healthcare processes as complete data of high
resolution in a way that minimally interferes with the
healthcare deliverer’s workflow [20].
In this manuscript, we present a complete and
in-depth analysis of global antibiotic prescription and in-
fection diagnosis in a university hospital ICU over a
4-year period. These data were collected with the help of
a locally developed software program, which has been
designed to link pharmaceutical, clinical and microbio-
logical data together with diagnostic interpretation while
performing daily bedside clinical work. As such, we were
able to get a bird’s eye view of our local antibiotic pre-
scribing practices, which can then serve as a starting
point for the future construction of an antibiotic stew-
ardship program (ASP).
Methods
Setting
This study was conducted from 1 January 2013 until 31
December 2016 at the medical (14 beds) and surgical
(22 beds) ICU of Ghent University Hospital (1054 beds).
The Ghent University Hospital Ethics Committee approved
the study (registration number B670201628197) and waived
informed consent based on the non-interventional nature
of this study and the complete anonymization of patient
data. Patients aged 16 years or older were included.
An Intensive Care Information System (Centricity
Critical Care, GE Health Care) integrating computerized
physician order entry for medication prescriptions, com-
puterized medication administration recording and clin-
ical patient monitoring data has been available at the
bedside since 2003. Patients are managed in a closed
ICU model. Antibiotic prescriptions are at the discretion
of the attending senior ICU physician, without the use
of stringent protocols or antibiotic restrictions. As a rule,
postoperative prophylactic treatment is not prolonged
for more than 24 h following the procedure. Empirical
antibiotic choices are guided by systematically collected
surveillance cultures whenever available. Direct micro-
scopic examination is performed on all diagnostic respira-
tory and per-operative samples. Pathogen identification is
routinely performed by matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF
MS). Microbiology results are reported electronically.
Interdisciplinary staff meetings with medical microbiolo-
gists reviewing all antibiotic prescriptions take place once
weekly in the medical ICU and three times weekly in
the surgical ICU; these staff also include the presence
of infectious diseases specialists in the surgical ICU. In
addition, daily advice and follow up by these specialties
is possible on a demand basis. Treatment duration and
opportunities for antibiotic de-escalation are evaluated
daily by the attending ICU physician and during the
interdisciplinary discussions.
A ventilation-associated pneumonia (VAP) prevention
bundle was used during the entire study period and in-
volved the use of strict hand hygiene, oral care with
chlorhexidine, endotracheal tube cuff pressure control
(between 20 and 30 cm of H2O), a semi-recumbent pos-
ition (30–45°) and daily assessment of sedation.
A software program with the acronym COSARA
(Computer-based Surveillance and Alerting of infections,
antimicrobial Resistance and Antibiotic consumption in
the ICU) was developed by a consortium of the Ghent
University Hospital ICU and the Department of Informa-
tion Technology (INTEC) of the Faculty of Engineering of
Ghent University [20]. The project was funded by the
Flemish government. The software has been fully oper-
ational since 2010 at the study ICU and since then its use
has become incorporated into routine daily patient care
(e.g. during ward rounds and interdisciplinary staff meet-
ings). The goal of COSARA is to support the physician in
the daily workflow by automatically integrating all relevant
infection-related data (clinical parameters, antibiotic pre-
scription, laboratory variables including microbiology and
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chest x-ray images) from different data sources and pre-
senting these as a graphic overview (Additional files 1,
2, 3 and 4). The validity of COSARA as a surveillance
tool and the feasibility of continued infection registra-
tion through the software has been described in a pre-
ceding study [21]. With the help of COSARA, all
antibiotic prescriptions are prospectively labeled: diag-
nostic (suspected focus, severity and probability of in-
fection, or prophylaxis) and microbiological information
is first entered into the system by ICU physicians at the
time of antibiotic prescription, which is then definitively
reassessed by dedicated ICU physicians (LDB and PD)
at patient discharge. Probability is classified as low,
moderate or high, as described previously [21], using
clinical, radiological and microbiological criteria.
Prescription indication and antimicrobial utilization
were described for all patients that were admitted during
this study period. In microbiologically confirmed infec-
tions, the timing of appropriate antibiotic therapy was
defined as the point in time at which all pathogens in-
volved in the infection were covered by at least one
component of the treatment.
Antimicrobial days of therapy (DOT) per admission
and per patient days is recommended as utilization
metric by the STEWARDS panel and others [13, 14, 22].
In agreement with the recommendations of the Centers
for Disease Control and Prevention - National Health-
care Safety Network (CDC-NHSN), DOT is defined as
the number of days with systemic administration of at
least one dose of an antimicrobial agent as recorded by
COSARA [12].
Subgroup analyses were performed in the patient pop-
ulations with an ICU length of stay (LOS) equal to or
more than 48 h versus less than 48 h, respectively, as
this latter subgroup consists mainly of the less severely
ill patients in our setting (e.g. patients who are postoper-
ative, have minor trauma or are being monitored). In
addition, patients with an ICU LOS of 48 h or more
constitute the population at risk of developing
ICU-acquired infection, which was defined as an infec-
tion emerging after more than 48 h of ICU admission.
Statistics
Categorical variables were expressed as frequencies
(percentages) and continuous variables were described
as medians with the interquartile range (IQR; 25–75th
percentile). Differences in categorical variables were
calculated using the Pearson chi-square test. The
Mann–Whitney U test was used to compare continuous
variables. Statistical significance was defined as p < 0.05.
For outcome analysis, we only included the last ICU epi-
sode of patients with consecutive ICU admissions. Stat-
istical analysis was performed using R Statistical
Software (version 3.4.2).
Results
Patients
A total of 10,743 ICU admissions were recorded in 8763
patients, resulting in a total of 47,403 patient days from 1
January 2013 until 31 December 2016. ICU and hospital
mortality were 10.7% and 15%, respectively. Median Acute
Physiology and Chronic Health Evaluation (APACHE) II
score at admission was 18 (IQR 13–25). Mechanical venti-
lation was provided in 3958 admissions (36.8%) with a me-
dian duration of 2 days (IQR 1–6), resulting in 20,897
ventilation days. Vasopressor therapy was administered in
3639 admissions (33.9%) with a median duration of 2 days
(IQR 2–4). Detailed information on patient characteristics
is presented in Additional file 5.
Methicillin resistance was present in 23% of the
Staphylococcus aureus isolates in our ICU population.
Vancomycin resistance was present in 1.9% of the
Enterococcus species isolates. Extended spectrum
beta-lactamase production (ESBL) was present in 33% of
Enterobacteriaceae isolates, whereas carbapenemase pro-
duction was present in 1.2%.
Patients were exposed to at least one antibiotic class
in 66% (7051/10743) of ICU admissions. An infection
was present within the first 48 h of ICU admission in
35% (3804/10743) of admissions. An ICU-acquired in-
fection was diagnosed in 23% (1096/4851) of admissions
with an ICU length of stay of more than 48 h. Detailed
information on antibiotic exposure per ICU episode is
provided in Fig. 1.
Prescription indication
A total number of 10,731 treatment courses (infection
bars) was recorded during the study period. Respectively
4525 (42.2%) and 6206 (57.8%) of these courses were pre-
scribed for prophylaxis and for infection. Fungal infections
represented 8% (520/6206) of the infectious episodes. In-
fections were microbiologically confirmed in 56% (3169/
5686) and 63% (327/520) of bacterial and fungal infec-
tions, respectively. Antibiotic treatment initiated in the
ICU was considered appropriate within 12 h and 24 h, re-
spectively, following treatment initiation in 83% and 87%
of microbiologically confirmed infections. Infections were
ICU-acquired in 28% of cases (1767/6206). The focus of
the bacterial infections was predominantly respiratory and
abdominal (respectively, 49% and 19%). The crude ICU
mortality rate in patients with respiratory and abdominal
infections was 22.1% and 19.2%, respectively. Infection
probability was classified as high, moderate or low in 50%,
34% and 16%, respectively, of the respiratory infections
compared to 76%, 16% and 8%, respectively, of the ab-
dominal infections. The median treatment duration of
high, moderate and low probability respiratory infections
for which the course was completed on the ICU was 7 days
(IQR 5–10), 6 days (IQR 4–8)] and 4 days (IQR 2–6),
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respectively. Only 19% of the respiratory infections were
classified as ventilator-associated. A total of 345 cases of
VAP and 182 cases of ventilator-associated tracheobron-
chitis (VAT) were diagnosed, resulting in VAP and VAT
incidences of 16.5/1000 ventilation days and 8.7/1000 ven-
tilation days, respectively. Respectively, 52%, 37% and 11%
of VAP were classified as having a high, moderate or low
probability of infection, translating into VAP incidences of
8.6, 6.1 and 1.8/1000 ventilation days, respectively. VAP
incidence was 17.0/1000 ventilation days in the medical
ICU and 16.1/1000 ventilation days in the surgical ICU.
The median treatment duration of VAP and VAT episodes
in the ICU was 7 days (IQR 5–9) and 6 days (IQR 4–7),
respectively. The crude ICU mortality rate in patients with
VAP and VAT was 32.6% and 21.1%, respectively (see Fig. 2
for more details on bacterial and fungal infection focus).
Additional file 6 contains more details on treatment dur-
ation per infection focus.
Antimicrobial utilization
A total of 14,908 antibiotic courses (antibiotic bars) were
administered, resulting in 58,413 DOT (1232 DOT/1000
patient days). Detailed utilization analysis per antibiotic
agent and infection probability is presented in Table 1.
Utilization analysis per antibiotic agent per year is presented
in Additional file 7. Anti-pseudomonal penicillins combined
with a beta-lactamase inhibitor, non-anti-pseudomonal pen-
icillins combined with a beta-lactamase inhibitor and fluor-
oquinolones were the most frequently used classes of
antibiotics (respectively, 218 DOT/1000 patient days, 172
DOT/1000 patient days and 114 DOT/1000 patient days);
azoles were the predominantly used class of antifungal drug
(162 DOT/1000 patient days).
Prophylactic therapy accounted for 25% of the total anti-
microbial DOT; first-generation cephalosporins, folate
pathway inhibitors, monobactams and azoles were pre-
dominantly used in this setting. Antibacterial prophylaxis
mainly comprised perioperative prophylaxis (46%) and
prolonged prophylaxis in the immunosuppressed patient
(19%). The median duration of perioperative prophylaxis
was 8 h (IQR 8–17). In addition, 9% and 11%, respectively,
of antibacterial prophylaxis was initiated in the setting of
trauma and following aspiration with respective durations
of 3 DOT (IQR 2–4) in trauma patients and 3 DOT (IQR
2–5) in the setting of aspiration. Antifungal prophylaxis
accounted for 53% of the total antifungal DOT and was
primarily administered in the surgical ICU (76%), with a
median duration of 4 DOT (IQR 2–9).
Fig. 1 Antibiotic exposure per ICU episode. ab, antibiotic; ICU, intensive care unit; LOS, length of stay
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Seventy-five percent of the total antimicrobial DOT was
used to treat infections. Of the total amount of DOT used
to treat bacterial respiratory infections, 42% was used to
treat infections with a moderate and low probability; for
bacterial abdominal infections, this figure was 15%.
Microbiology
Enterobacteriaceae were the predominant bacterial spe-
cies that were designated as causative pathogens in both
respiratory and abdominal infections (respectively, 39% and
46% of all pathogens linked). Amoxicillin/clavulanic acid re-
sistance and cefuroxime resistance was present in 48% and
39% of the Enterobacteriaceae isolates, respectively.
Non-fermenting Gram-negative bacilli were the second
most prevalent pathogens associated with respiratory infec-
tions (15%), and mainly consisted of Pseudomonas aerugi-
nosa. Piperacillin-tazobactam, ceftazidime and meropenem
resistance was present in 27%, 20% and 20%, respectively,
of the Pseudomonas isolates. Enterococci were the second
most prevalent pathogens that were linked as causative in
the abdominal infections (20%) and ampicillin resistance
was present in 44% of the isolates (Fig. 3).
Discussion
In this manuscript, we demonstrated the versatility of a
detailed database in antibiotic use and infection diagno-
sis, which is prospectively built by linking prescription,
clinical and microbiological data on individual ICU pa-
tients during clinical workflow. This allowed various
analyses that respectively center on patient admissions,
prescription indication and infection diagnosis, antibiotic
utilization and microbiology and as such may be useful
to support various aspects of infection control and anti-
biotic stewardship. To the best of our knowledge, our
a b
c d
Fig. 2 Bacterial and fungal infection focus. a Focus of bacterial infections (n = 5686); infection probability was classified as low, moderate or high
in 14%, 27% and 59% of the bacterial infections, respectively; CLABSI, central-line-associated bloodstream infection. CLABSI incidence was 3.8/
1000 catheter days. Crude ICU mortality rate in patients with CLABSI was 11.4%. b Focus of fungal infections (n = 520); infection probability was
classified as low, moderate or high in 12%, 17% and 71% of the fungal infections, respectively; °presence of yeast in a normally sterile body site
combined with clinical signs of infection; *fungal infection considered clinically likely by treating physician in the absence of yeast in a normally
sterile body site; ^mucocutaneous candidiasis, candidiasis of the genitourinary tract, extra-pulmonary Aspergillus infection, invasive non-Aspergillus
mold infection. c Bacterial respiratory infection (n = 2779); °bacterial pneumonia following macroaspiration; *tracheobronchitis criteria include
fever, purulent tracheobronchial secretions, isolation of a respiratory pathogen of a good quality lower respiratory tract sample, no radiographic
signs of new pneumonia. d Bacterial abdominal infection (n = 1094)
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study is the largest single-center study providing epi-
demiological data on antibiotic consumption and infec-
tions treated in the ICU in terms of number of ICU
beds (36) and timespan covered (4 years).
Our study confirms that the antibiotic burden in the ICU
is very high. Respectively, 66% of all admitted patients and
84% of patients with an ICU stay of more than 48 h were
exposed to at least one class of antibiotic. These figures are
consistent with the results of the one-year prospective sur-
veillance study of Bergmans et al. and with the EPIC II
point-prevalence study, which reported antibiotic prescrip-
tion in 61% and 71% of admitted patients, respectively [1, 2].
The need for detailed antibiotic prescription surveillance
and feedback to the clinician was already acknowledged in
the very early stages of antimicrobial stewardship, but
there is disagreement about which appropriate measures
to select [5, 13, 14, 23, 24]. In 2016, the consensus results
of an expert panel on metrics assessing the impact of
stewardship interventions on a patient level in an
acute-care setting were published. Potential metrics were
Table 1 Antimicrobial utilization per antimicrobial class and per infection probability
DOT (%) DOT/1000
patient days
DOT (% of total DOT/antibiotic class)
Infection present Prophylactic treatment
High
probability
Moderate
probability
Low
probability
Antibacterial class
Aminoglycosides 474 (1.0) 10.0 388 (81.8) 67 (14.1) 5 (1.1) 6 (1.3)
Ansamycins (rifampicin) 268 (0.5) 5.7 230 (85.8) 9 (3.4) 13 (4.9) 15 (5.6)
Carbapenems 4488 (9.1) 94.7 3438 (76.6) 697 (15.5) 221 (4.9) 110 (2.5)
1st gen. cephalosporins 2939 (6.0) 62.0 – – – 2939 (100)
2nd gen. cephalosporins 1192 (2.4) 25.1 398 (33.4) 324 (27.2) 169 (14.2) 301 (25.3)
3rd gen. cephalosporins 1955 (4.0) 41.2 1343 (68.7) 400 (20.5) 143 (7.3) 63 (3.2)
Fluoroquinolones 5385 (11) 113.6 3268 (60.7) 1285 (23.9) 367 (6.8) 448 (8.3)
Folate pathway inhibitor 3105 (6.3) 65.5 896 (28.9) 319 (10.3) 142 (4.6) 1747 (56.3)
Glycopeptides 2966 (6.0) 62.6 2163 (72.9) 438 (14.8) 172 (5.8) 169 (5.7)
Glycylcyclines 319 (0.6) 6.7 242 (75.9) 63 (19.7) 11 (3.4) 2 (0.6)
Lincosamides 806 (1.6) 17.0 564 (70.0) 140 (17.4) 42 (5.2) 60 (7.4)
Macrolides 1421 (2.9) 30.0 834 (58.7) 215 (15.1) 84 (5.9) 284 (20.0)
Monobactams 150 (0.3) 3.2 33 (22.0) 28 (18.7) 10 (6.7) 79 (52.7)
Nitrofurans 59 (0.1) 1.2 19 (32.2) 16 (27.1) 7 (11.9) 17 (28.8)
Nitroimidazoles 1289 (2.6) 27.2 976 (75.7) 147 (11.4) 61 (4.7) 92 (7.1)
Oxazolidinones 1780 (3.6) 37.6 1434 (80.6) 212 (11.9) 53 (3.0) 69 (3.9)
Penicillins 1504 (3.1) 31.7 1212 (80.6) 188 (12.5) 86 (5.7) 15 (1.0)
Non-anti-pseudomonal penicillins + beta-lactamase
inhibitor
8136 (16.5) 171.6 3267 (40.2) 1605 (19.7) 660 (8.1) 2588 (31.8)
Anti-pseudomonal penicillins + beta-lactamase
inhibitor
10,342 (21.0) 218.2 6405 (61.9) 2292 (22.2) 808 (7.8) 800 (7.7)
Phosphonic acids 27 (0.1) 0.6 3 (11.1) 17 (63.0) 6 (22.2) 1 (3.7)
Polymyxins 469 (1.0) 9.9 311 (66.3) 97 (20.7) 19 (4.1) 42 (9.0)
Tetracyclines 95 (0.2) 2.0 82 (86.3) 1 (1.1) 1 (1.1) 11 (11.6)
Total antibacterial 49,169 (100) 1037.3 27,506 (55.9) 8560 (17.4) 3080 (6.3) 9858 (20.0)
Antifungal class
Azoles 7684 (83.1) 162.1 2123 (27.6) 415 (5.4) 222 (2.9) 4809 (62.6)
Echinocandins 1354 (14.6) 28.6 1022 (75.5) 176 (13.0) 93 (6.9) 56 (4.1)
Polyenes 206 (2.2) 4.3 138 (67.0) 37 (18.0) 29 (14.1) –
Total antifungal 9244 (100) 195.0 3283 (35.5) 628 (6.8) 344 (3.7) 4865 (52.6)
Total 58,413 (100) 1232.3 30,789 (52.7) 9188 (15.7) 3424 (5.9) 14,723 (25.2)
DOT days of therapy, gen. generation
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evaluated for four distinct criteria, one of them being the
feasibility to monitor the metric in any hospital with an
electronic health record. Only six metrics were retained
by the expert panel as suitable for ready implementation:
incidence of healthcare facility and hospital-onset Clos-
tridium difficile infection, rates of antibiotic-resistant
pathogens, days of antibiotic therapy/number of admis-
sions, days of antibiotic therapy/patient days and redun-
dant therapy events. All of these metrics may be derived
from separate electronic data sources (clinical, pharmacy,
microbiology) and a connection between the different ele-
ments is not mandatory; however, these metrics are crude
and unable to provide insight into antibiotic prescription.
By linking these sources, a deeper understanding of the
different factors driving antimicrobial use can be obtained,
as illustrated by this study.
For example, the respiratory system accounted for half
of identified sources of bacterial infection and more than
one third of the total antibacterial DOT. Compared to ab-
dominal infections, which represented the second largest
group of bacterial infections and destination for antibiotic
consumption, respiratory infections were less frequently
categorized as highly probable (76% versus 50%, respect-
ively), which also reflected the amount of DOT that was
designated to treat these highly probable infections (85%
of the total DOT of abdominal and 56% of the total DOT
of respiratory infections). One quarter of the infections
that were diagnosed in our ICU were ICU-acquired, which
is in contrast with the study of Bergmans et al. where half
of the infections were ICU-acquired and almost exclu-
sively occurred in ventilated patients. Whereas the authors
of the previous study concluded that stewardship should
be focused on the prevention of ventilator-associated re-
spiratory infections, this statement may apply less to our
ICU population. In addition, restricting duration of anti-
biotic therapy in VAP of high probability will offer little
gain, as the median treatment duration was only 7 days. In
contrast, more restrictive use of antibiotics in suspected
respiratory tract infections with cultures remaining nega-
tive and/or a swift clinical resolution, could result in a
more profound reduction of antibiotic consumption. In
addition, we observed that prophylactic treatment
accounted for one fourth of the total DOT. Although this
figure seems extremely high, more in-depth evaluation
showed that two thirds of the antibacterial prophylactic
treatment consisted of perioperative prophylaxis and
prophylaxis in the immunocompromised patient, which
conformed to guidelines with regard to treatment dur-
ation in the ICU. Whether aspiration and trauma justify
antibiotic prophylaxis, and for what duration, is still a
matter of debate; more recent studies promote restrictive
use of antibiotics in this setting [25–29]. We believe that
introduction of more restrictive guidelines on prophylaxis
in trauma and aspiration, which are currently unavailable
in our ICU, could lead to a reduction in antibiotic use, al-
beit rather limited if we take the total as well as the me-
dian DOT for both indications in our ICU into account.
This is in contrast with use of the antifungal prophylactic
a b
Fig. 3 Pathogens linked to bacterial respiratory and abdominal infections. a Pathogens linked to bacterial respiratory infection (n = 1828);
Enterobacteriaceae = Citrobacter spp., Enterobacter spp., Escherichia coli, Hafnia spp., Klebsiella spp., Morganella spp., Proteus spp., Providencia spp.,
Serratia spp. Non-fermenting Gram-negative bacilli = Achromobacter spp., Acinetobacter spp., Stenotrophomonas spp., Pseudomonas spp., other
non-fermenting Gram-negative bacilli. Streptococcus spp. = Streptococcus pneumoniae, Streptococcus pyogenes, Viridans streptococci, other
streptococci. Other = culture results of referral hospital. Serologic diagnosis = Legionella pneumophila antigen, Streptococcus pneumoniae antigen.
b Pathogens linked to bacterial abdominal infection (n = 1403); Enterobacteriaceae = Citrobacter spp., Enterobacter spp., Escherichia coli, Hafnia spp.,
Klebsiella spp., Morganella spp., Proteus spp., Providencia spp., Salmonella spp., Serratia spp., Yersinia spp. Enterococcus spp. = Enterococcus faecalis,
Enterococcus faecium, other enterococci. Other = culture results of referral hospital. Non-fermenting Gram-negative bacilli = Achromobacter spp.,
Stenotrophomonas spp., Pseudomonas spp., other non-fermenting Gram-negative bacilli. Streptococcus spp. = Streptococcus pneumonia, Viridans
streptococci, other streptococci. Staphylococcus spp. = Staphylococcus aureus, coagulase-negative staphylococci, other. Other Gram-negative = e.g.
Bacteroides spp., Prevotella spp., Aeromonas spp., Campylobacter spp. Other Gram-positives = e.g. Clostridium spp., Bacillus spp.
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treatment, which is extremely high in our ICU, particu-
larly in the context of intra-abdominal infections. Clear in-
structions on prophylactic indication and treatment
duration, which are also not in place, may restrain our
overall use of antifungals [30].
Despite the recognition of the importance of
high-quality surveillance data to support antibiotic stew-
ardship, few studies have provided detailed data on ICU
global antibiotic consumption and infection diagnosis over
an extended period of time [1, 19, 31]. This may reflect the
difficulties in continuous prospective collection of
infection-related data due to personnel and time restraints.
In fact, while the authors of the study of Bergmans et al.
felt that their proposed surveillance model in which they
categorize antibiotic indications as prophylaxis, bacterio-
logically proven infections or non-bacteriologically proven
(clinical suspicion) infections, would be suitable for more
widespread use, there have since been few publications of-
fering a similarly wide scope on antibiotic use in the ICU
[1]. In our ICU, the COSARA software platform facilitated
the integration of antibiotic, clinical and microbiological
information during the workflow of daily bedside clinical
rounds and weekly multidisciplinary staff meetings, hereby
illustrating that sustained prospective surveillance is an
achievable ambition with the help of information technol-
ogy [20, 21]. The sustainability of this surveillance is prob-
ably to a certain extent due to the rather intuitive approach
of labeling infections by the physician choosing from a
drop-down menu of possible diagnoses and categorization
by infection probability. While the result closely reflects
physicians’ judgment and attitude in daily practice, it does
not formally adhere to criteria such as those provided by
the Centers for Disease Control (CDC) or the European
Centre for Disease Prevention and Control (ECDC). A pre-
vious analysis assessing the validity of the diagnostic infor-
mation recorded as such in COSARA compared to
conventional surveillance data gathered by using checklists
based on CDC-NHSN criteria showed good agreement be-
tween both surveillance methods [21]. However, a lack of
precision may hamper comparisons between centers (as re-
quired for benchmarking) and over time (changing percep-
tion). This may to a certain extent be remedied by filtering
sets of infection labels for the fulfillment of objective cri-
teria as e.g. presence of positive microbiological cultures,
biochemical findings exceeding a given threshold and not-
ing of clinical signs in a computerized medical file.
Our study has limitations. First, building the database
starting from computerized physician order entry de-
pends on adequate filling in of the “pop-up” questions
that are triggered by it, and by the persistent commit-
ment of attending physicians or infection control
personnel in linking the various information sources and
finalizing infection diagnosis. Second, as stated before, the
lack of adherence to strict criteria in labeling infection
diagnosis in the current design hampers multicenter appli-
cation [21]. Probably a trade-off has to be found between
practical feasibility of continued registration on the one
hand, and precision in diagnosis on the other. In addition,
while COSARA software is compatible with various inten-
sive care information systems, the applicability of our sur-
veillance in different ICU settings and staffing structures
has not been formally tested. Therefore, further studies
are necessary to validate this model in these settings.
Third, COSARA does not capture infections for which no
antibiotic treatment is prescribed. Fourth, it remains to be
tested to what extent high-quality surveillance may trans-
late into effective stewardship intervening in the treatment
decisions of the ICU physician.
Conclusions
We were able to obtain a unique bird’s eye view on glo-
bal antibiotic use and infection diagnosis in our ICU
over a 4-year time period by analysis of a multifaceted
dataset, which was collected during the daily clinical
workflow of ICU physicians with the help of informa-
tion technology. In doing so, we revealed antibiotic pre-
scription patterns that merit the attention of antibiotic
stewardship.
Additional files
Additional file 1: Screenshot of COSARA central infection dashboard
view. Time-graphs at the top of the page show the evolution of selected
clinical (e.g. fever) and laboratory (e.g. leukocytosis, C-reactive protein
(CRP)) variables and indicators of severity-of-illness (e.g. the arterial
oxygen tension (PaO2)/fractional inspired oxygen (FiO2) ratio, sequential
organ failure assessment score (SOFA)). For every antibiotic prescription
that is entered via computerized physician order entry, a horizontal bar is
created that runs just above the timeline and lengthens upon duration of
the prescription (antibiotic bar). This bar is accompanied by a second bar
running in parallel below the timeline and describing the indication for
this antibiotic (infection bar - introduced manually and structured). The
infection bar is created in a two-step fashion. A preliminary version is fed
by data from a short questionnaire that “pops up” in real time after any
antibiotic prescription and inquires the prescriber about indication, likely
focus, severity and probability of infection and presence of microbiological
data guiding antibiotic choice. This preliminary bar can be altered manually
when more data on the origin and clinical evolution of the infection
become available. Multiple antibiotic prescriptions can thus be linked with
the same infection bar; in addition, the same antibiotic bar can be linked
with multiple infection bars (e.g. antibiotic prescribed for simultaneous
intra-abdominal and respiratory infection). For each infectious episode,
focus, severity and probability of infection is selected from a drop-down
menu. More detailed information on prescription and infection are revealed
on the base of the screen by hovering over the bars. All positive microbial
culture results and matching susceptibility patterns are automatically
indicated above the timeline using small symbols, whereas selected
microbiological isolates that are linked to an infection are displayed
underneath the timeline. (JPG 479 kb)
Additional file 2: Screenshot of COSARA microbiology overview. The
results of consecutive microbiological samples that were taken in an
individual patient and the corresponding susceptibility patterns are
displayed. (JPG 511 kb)
Additional file 3: Screenshot of COSARA antibiotic-infection combinations
linked to microbiology data overview. The coupled antibiotic-infection bars
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can be linked to microbiological culture results; pathogens may be designated
as causative pathogens or as non-causative pathogens influencing antibiotic
prescription (e.g. nasal carriage of methicillin-resistant Staphylococcus aureus
promoting glycopeptide prescription in suspected pneumonia with negative
sputum cultures). (JPG 298 kb)
Additional file 4: Screenshot of COSARA consecutive chest x-rays view.
(JPG 474 kb)
Additional file 5: Patient characteristics. (DOC 36 kb)
Additional file 6: Treatment duration per focus of infection. (DOC 41 kb)
Additional file 7: Antimicrobial use per antimicrobial class and per year.
(DOC 61 kb)
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